- |||||||||| Gemiglo (gemigliptin) / Sanofi, LG Chem
Enrollment closed: An Ascending Dose, Single/Multiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I) (clinicaltrials.gov) - Aug 7, 2019 P1, N=48, Active, not recruiting, When comparing the AUC and C of gemigliptin, LC15-0636, and metformin, the 90% CIs were all within the range of 0.8 - 1.25, which is the commonly accepted range for evaluating bioequivalence. Not yet recruiting --> Active, not recruiting
- |||||||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion date, Trial primary completion date, Metastases: Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) - Jun 25, 2019 P2, N=5, Active, not recruiting, 1604-138-758). Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2019 --> Dec 2019
- |||||||||| Fotivda (tivozanib) / EUSA Pharma, AVEO
Clinical, Review, Journal: Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives. (Pubmed Central) - Jun 14, 2019 Nowadays, in first-line and second-line treatment of mRCC, there is an abundance of options, mainly consisting of VEGFR-directed tyrosinekinase inhibitors. This review focusses on the role of tivozanib with respect to patient selection and future perspectives in this fast-changing landscape.
- |||||||||| Lantus (insulin glargine) / Sanofi, Basalin (insulin glargine biosimilar) / Gan & Lee Pharma, LG Chem, Sandoz
Enrollment open, Trial completion date: Effects of Replacing Lantus With Basalin on the Glycemic Variation in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Jun 11, 2019 P4, N=100, Recruiting, This review focusses on the role of tivozanib with respect to patient selection and future perspectives in this fast-changing landscape. Not yet recruiting --> Recruiting | Trial completion date: Jan 2019 --> Jul 2019
- |||||||||| Fotivda (tivozanib) / EUSA Pharma, AVEO
Journal: The role of tivozanib in advanced renal cell carcinoma therapy. (Pubmed Central) - Apr 11, 2019 Here the selectivity of tivozanib may contribute to an acceptable tolerability profile when used in combination therapy. Expert Commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting.
- |||||||||| ficlatuzumab (AV-299) / LG Chem
Trial primary completion date: Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (clinicaltrials.gov) - Mar 7, 2019 P1, N=24, Recruiting, Expert Commentary: The approval of tivozanib provides an additional option for the first-line treatment of advanced or metastatic RCC patients in Europe and allows use of a VEGFR-TKI with selectivity for VEGFRs in this setting. Trial primary completion date: Jun 2019 --> Dec 2019
- |||||||||| Euvax B (recombinant hepatitis B vaccine) / LG Chem
Trial completion, Trial completion date, Trial primary completion date: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Jan 25, 2019 P4, N=132, Completed, Trial primary completion date: Jun 2019 --> Dec 2019 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Apr 2017 | Trial primary completion date: Jul 2018 --> Apr 2017
- |||||||||| ficlatuzumab (AV-299) / LG Chem
Biomarker, Phase classification, Enrollment change, Trial termination, Trial primary completion date, Metastases: Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 3, 2019 P1b, N=1, Terminated, Active, not recruiting --> Completed Phase classification: P1 --> P1b | N=24 --> 1 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Sep 2016; the investigator left the institution
- |||||||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Trial completion date, Trial primary completion date, Metastases: Tivozanib + Enzalutamide in Adv Prostate Cancer (clinicaltrials.gov) - Dec 11, 2018 P2, N=5, Active, not recruiting, Phase classification: P1 --> P1b | N=24 --> 1 | Suspended --> Terminated | Trial primary completion date: Jun 2018 --> Sep 2016; the investigator left the institution Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- |||||||||| Zemimet SR (gemigliptin/metformin sustained release) / LG Chem
Trial completion date, Trial primary completion date, Combination therapy: INTESTINE: Initial Combination of Gemigliptin and Metformin on Microbiota Change (clinicaltrials.gov) - Oct 24, 2018 P=N/A, N=70, Recruiting, Trial completion date: Dec 2017 --> Feb 2020 | Trial primary completion date: Dec 2017 --> Mar 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Apr 2019
- |||||||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment closed, Trial primary completion date: Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov) - Aug 14, 2018 P2, N=28, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Aug 2020 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2018 --> Mar 2019
- |||||||||| Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
Enrollment closed, Trial completion date, Combination therapy, Metastases: TiNivo study : Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC (clinicaltrials.gov) - Jun 26, 2018 P1/2, N=28, Active, not recruiting, Recruiting --> Completed | Trial primary completion date: Mar 2018 --> Dec 2017 Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018
- |||||||||| ficlatuzumab (AV-299) / LG Chem
Trial completion date, Trial primary completion date: Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML (clinicaltrials.gov) - Jun 25, 2018 P1, N=24, Recruiting, Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2019
- |||||||||| Besivo (besifovir) / Gilead, LG Chem, Ildong
Enrollment closed, Trial completion date: Phase 3 and Extensional Study of Besifovir (clinicaltrials.gov) - Mar 20, 2018 P3, N=197, Active, not recruiting, N=350 --> 230 Recruiting --> Active, not recruiting | Trial completion date: Jan 2016 --> Jan 2023
|